Voyager Therapeutics, Inc. — Form 8-K/A
Filed November 18, 2026 · analyzed by the 8-K Agent
8-K/A
— Neutral
significance 48/100
What the filing says
Voyager ended Q3 2026 with $132.1M cash (down from $201.7M at year-end 2025), sufficient to fund operations into Q2 2028. VY7523 (anti-tau antibody) enrollment complete; tau PET imaging data expected Q4 2026. VY1706 (tau gene therapy) patient dosing expected within months; Neurocrine's NBIB-'223 (Friedreich's ataxia) entering clinic imminently. Q3 net loss $24.7M (vs. $27.9M prior year); collaboration revenue fell to $4.0M (from $13.4M) as Neurocrine program transitions past research phase.
Why this rating
Cash runway extension and clinical milestones are positive; but 34% cash burn in 9 months (from $201.7M to $132.1M) and declining partner revenue are concerning. Event is material relative to $144.2M market cap but company remains solvent through mid-2028.
See more from November 18, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.